IL23 Promotes Antimicrobial Pathways in Human Macrophages, Which Are Reduced With the IBD-Protective IL23R R381Q Variant

BACKGROUND & AIMS: Interleukin (IL)23 is a major contributor to inflammatory bowel disease (IBD) pathogenesis and is being pursued as a therapeutic target, both through targeting IL23 alone or in combination with IL12. Unexpected trial outcomes highlight the importance of understanding the cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Rui, Abraham, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490566/
https://www.ncbi.nlm.nih.gov/pubmed/32474165
http://dx.doi.org/10.1016/j.jcmgh.2020.05.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490566/
https://www.ncbi.nlm.nih.gov/pubmed/32474165
http://dx.doi.org/10.1016/j.jcmgh.2020.05.007

Ejemplares similares